Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease
Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease
Late stage lower extremity arterial disease (LEAD) is known to be associated with hemodynamic
 and metabolic abnormalities and very poor long-term prognosis. The prognostic value of
 hemodynamic and metabolic profiling, however, is yet to be determined in this patient group.

 Current study aims to identify novel prognostic biomarkers for better risk stratification of
 late stage LEAD patients. It also allows to determine associations between
 hemodynamic/arterial stiffness indices, low-molecular weight metabolites and other substances
 (e.g. mediators of inflammation and bone-mineral metabolism, cardiac and kidney injury
 biomarkers, microRNAs) thus providing potentially valuable insight into the pathogenic
 mechanisms of this disease.
Exclusion Criteria:

 -  Fontaine stage I-IIa;

 -  acute limb ischemia;

 -  age <35 or >85 years;

 -  fasting < 6 hours;

 -  time since the last use of tobacco products < 4 hours;

 -  body mass index ≥ 40 kg/m2

 -  blood pressure ≥ 180/120mmHg;

 -  unstable angina;

 -  atrial fibrillation at the time of presentation;

 -  myocardial infarction, stroke or TIA during the preceding 3 months;

 -  any revascularization during the preceding 1 month;

 -  severe heart failure (NYHA IV);

 -  clinically significant heart valve disease;

 -  severe physical disability (other than limb ischemia);

 -  acute infectious disease;

 -  active malignancy or chemotherapy or disease-free < 5 years;

 -  type 1 diabetes;

 -  uncompensated thyrotoxicosis/hypothyroidism or other clinically significant endocrine
 disorders;

 -  moderate to severe asthma (GINA 2016);

 -  severe chronic obstructive pulmonary disease (mMRC grade 3-4)

 -  acute (KDIGO 2012) or chronic renal disease (eGFR-EPI <30mL/min/1.73 m2);

 -  clinically significant acute or chronic liver disease;

 -  severe anemia (<80 g/L);

 -  clinically significant neuroinflammatory or neurodegenerative disease;

 -  active rheumatism;

 -  clinically significant connective tissue disease;

 -  alcoholism or drug abuse;

 -  psychotic disorders